Skip to main content
SpringerLink
Log in

Principles and Overview of Allogeneic Hematopoietic Stem Cell Transplantation

  • Chapter
  • First Online:
Hematopoietic Stem Cell Transplantation

Part of the book series: Cancer Treatment and Research ((CTAR,volume 144))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (two parts). N Engl J Med. 1975;292:832–43, 895–902.

    PubMed  CAS  Google Scholar 

  2. Weissman IL. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 2000;287:1442–6.

    PubMed  CAS  Google Scholar 

  3. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827–38.

    PubMed  CAS  Google Scholar 

  4. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003;9:702–12.

    PubMed  CAS  Google Scholar 

  5. Clark ML, Lynch FX. Clinical symptoms of radiation sickness, time to onset and duration of symptoms among Hiroshima survivors in the lethal and median lethal ranges of radiation. Mil Surg. 1952;111:360.

    PubMed  CAS  Google Scholar 

  6. Jacobson LO, Marks EK, Robson MJ, et al. Effect of spleen protection on mortality following X-irradiation. J Lab Clin Med. 1949;34:1538–43.

    Google Scholar 

  7. Rekers PE, Coulter MP, Warren S. Effects of transplantation of bone marrow into irradiated animals. Arch Surg. 1950;60:635.

    Google Scholar 

  8. Lorenz E, Uphoff DE, Reid TR, Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst. 1951;12:197–201.

    PubMed  CAS  Google Scholar 

  9. Barnes DW, Corp MJ, et al. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J. 1956;2:626–7.

    PubMed  CAS  Google Scholar 

  10. Dameshek W. Bone marrow transplantation; a present-day challenge. Blood 1957;12:321–3.

    PubMed  CAS  Google Scholar 

  11. Groth CG, Brent LB, Calne RY, et al. Historic landmarks in clinical transplantation: conclusions from the consensus conference at the University of California, Los Angeles. World J Surg. 2000;24:834–43.

    PubMed  CAS  Google Scholar 

  12. Van Rood JJ, Eernisse JG, et al. Leucocyte antibodies in sera from pregnant women. Nature 1958;181:1735–6.

    Google Scholar 

  13. Wilson RE, Henry L, Merrill JP. A model system for determining histocompatibility in man. J Clin Invest. 1963;42:1497–503.

    PubMed  CAS  Google Scholar 

  14. Dausset J, Rapaport FT, et al. A leucocyte group and its relationship to tissue histocompatibility in man. Transplantation 1965;3:701–5.

    PubMed  CAS  Google Scholar 

  15. Mathé G, Amiel JL, Schwartzenberg L, et al. Successful allogeneic bone marrow transplantation in man: chimerism, induced specific tolerance and possible antileukemic effects. Blood 1965:25:179–96.

    PubMed  Google Scholar 

  16. Bach FH, Albertini RJ, et al. Bone-marrow transplantation in a patient with the Wiskott–Aldrich syndrome. Lancet 1968;2:1364–6.

    PubMed  CAS  Google Scholar 

  17. Gatti RA, Meuwissen HJ, et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968;2:1366–9.

    PubMed  CAS  Google Scholar 

  18. De Koning J, Van Bekkum DW et al. Transplantation of bone-marrow cells and fetal thymus in an infant with lymphopenic immunological deficiency. Lancet 1969;1:1223–7.

    PubMed  Google Scholar 

  19. Thomas ED, Buckner CD, et al. Aplastic anemia treated by marrow transplantation. Lancet 1972;i:284–9.

    Google Scholar 

  20. Thomas ED, Buckner CD, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977;49:511–33.

    PubMed  CAS  Google Scholar 

  21. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26.

    PubMed  CAS  Google Scholar 

  22. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–73.

    PubMed  CAS  Google Scholar 

  23. Weiden PL, Sullivan KM, Flournoy N, et al. Anti-leukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529–33.

    PubMed  CAS  Google Scholar 

  24. Butturini A, Bortin MM, et al. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant. 1987;2:233–42.

    PubMed  CAS  Google Scholar 

  25. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555–62.

    PubMed  CAS  Google Scholar 

  26. Kolb HJ, Mittermüller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462–5.

    PubMed  CAS  Google Scholar 

  27. Porter DL, Roth MS, McGarigle C, et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330:100–6.

    PubMed  CAS  Google Scholar 

  28. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041–50.

    PubMed  CAS  Google Scholar 

  29. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–44.

    PubMed  Google Scholar 

  30. McCluskey J, Peh CA. The human leucocyte antigens and clinical medicine: an overview. Rev Immunogenet. 1999;1:3–20.

    PubMed  CAS  Google Scholar 

  31. Hurley CK, Wade JA, Oudshoorn M, et al. A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Tissue Antigens. 1999;53:394–406.

    PubMed  CAS  Google Scholar 

  32. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923–30.

    PubMed  CAS  Google Scholar 

  33. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313:765–71.

    PubMed  CAS  Google Scholar 

  34. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593–602.

    PubMed  CAS  Google Scholar 

  35. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1565–77.

    PubMed  CAS  Google Scholar 

  36. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–93.

    PubMed  CAS  Google Scholar 

  37. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24:5695–702.

    PubMed  Google Scholar 

  38. Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 2003;101:4233–44.

    PubMed  CAS  Google Scholar 

  39. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–75.

    PubMed  CAS  Google Scholar 

  40. Barker JN, Weisdorf DJ, Wagner JE. Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. N Engl J Med. 2001;344:1870–1.

    PubMed  CAS  Google Scholar 

  41. Fernandez MN, Regidor C, et al. Unrelated umbilical cord blood transplants in adults: early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. Exp Hematol. 2003;31:535–44.

    PubMed  Google Scholar 

  42. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997;89:3864–72.

    PubMed  CAS  Google Scholar 

  43. O‘Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, Rhubart P, Cowan K, Piantados S, Fuchs EJ. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–86.

    PubMed  Google Scholar 

  44. Buckner CD, Clift RA, Sanders JE, et al. Marrow harvesting from normal donors. Blood 1984;64:630–4.

    PubMed  CAS  Google Scholar 

  45. Seebach JD, Stussi G, Passweg JR, Loberiza FR Jr, Gajewski JL, Keating A, Goerner M, Rowlings PA, Tiberghien P, Elfenbein GJ, Gale RP, van Rood JJ, Reddy V, Gluckman E, Bolwell BJ, Klumpp TR, Horowitz MM, Ringdén O, Barrett AJ; GVHD Working Committee of Center for International Blood and Marrow Transplant Research. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant. 2005;11:1006–13.

    PubMed  Google Scholar 

  46. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A; Joint Accreditation Committee, International Society for Cellular Therapy; European Group for Blood and Marrow Transplantation. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant. 2006;37:1069–85.

    PubMed  CAS  Google Scholar 

  47. Stem Cell Trialists‘ Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074–87.

    Google Scholar 

  48. Rowley SD, Feng Z, Chen L, et al. A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch. Bone Marrow Transplant. 2003;31:1043–51.

    PubMed  CAS  Google Scholar 

  49. Simpson D. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation? BioDrugs 2003;17:147–54.

    PubMed  CAS  Google Scholar 

  50. Baranov A, Gale RP, Guskova A, et al. Bone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med. 1989;321:205–12.

    PubMed  CAS  Google Scholar 

  51. Niederwieser D, Maris M, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003;101:1620–9.

    PubMed  CAS  Google Scholar 

  52. Santos GW, Sensenbrenner LL, et al. HL-A-identical marrow transplants in aplastic anemia, acute leukemia, and lymphosarcoma employing cyclophosphamide. Transplant Proc. 1976;8:607–10.

    Google Scholar 

  53. Tutschka PJ, Copelan EA, et al. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987;70:1382–8.

    PubMed  CAS  Google Scholar 

  54. Andersson BS, Kashyap A, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study. Biol Blood Marrow Transplant. 2002;8:145–54.

    PubMed  CAS  Google Scholar 

  55. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531–6.

    PubMed  CAS  Google Scholar 

  56. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756–63.

    PubMed  CAS  Google Scholar 

  57. Antin JH. Clinical practice. Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med. 2002;347:36–42.

    PubMed  Google Scholar 

  58. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912–9.

    PubMed  CAS  Google Scholar 

  59. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989;73:606–13.

    PubMed  CAS  Google Scholar 

  60. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845–51.

    PubMed  CAS  Google Scholar 

  61. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138:705–13.

    PubMed  CAS  Google Scholar 

  62. Sullivan KM, Dykewicz CA, Longworth DL, Boeckh M, Baden LR, Rubin RH, Sepkowitz KA; Centers for Disease Control and Prevention; Infectious Diseases Society of America; American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program. 2001: 392–421.

    Google Scholar 

  63. Gruss E, Bernis C, Tomas JF, et al. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol. 1995;15:473–9.

    PubMed  CAS  Google Scholar 

  64. Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, Holler E, Iacobelli M, Kentouche K, Lämmle B, Moake JL, Richardson P, Socié G, Zeigler Z, Niederwieser D, Barbui T; European Group for Blood and Marrow Transplantation; European LeukemiaNet. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92:95–100.

    PubMed  Google Scholar 

  65. Srinivasan R, Balow JE, Sabnis S, et al. Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol. 2005;131:74–9.

    PubMed  CAS  Google Scholar 

  66. Bearman SI, Anderson GL, Mori M, et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol. 1993;11:1729–36.

    PubMed  CAS  Google Scholar 

  67. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22:27–42.

    PubMed  Google Scholar 

  68. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100:4337–43.

    PubMed  CAS  Google Scholar 

  69. Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, Snyder M, Lewis SK, Allerton JP, Thompson JM. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(12 Pt 1):975–81.

    PubMed  CAS  Google Scholar 

  70. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–8.

    PubMed  CAS  Google Scholar 

  71. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990;76:1464–72.

    PubMed  CAS  Google Scholar 

  72. Kennedy MS, Deeg HJ, Storb R, et al. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation: randomized study comparing corticosteroids and cyclosporine. Am J Med. 1985;78:978–83.

    PubMed  CAS  Google Scholar 

  73. Jacobsohn DA, Vogelsang GB. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 2002;62:879–89.

    PubMed  CAS  Google Scholar 

  74. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, Moresi JM, Greenson J, Janin A, Martin PJ, McDonald G, Flowers ME, Turner M, Atkinson J, Lefkowitch J, Washington MK, Prieto VG, Kim SK, Argenyi Z, Diwan AH, Rashid A, Hiatt K, Couriel D, Schultz K, Hymes S, Vogelsang GB. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006;12:31–47.

    PubMed  Google Scholar 

  75. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33.

    PubMed  CAS  Google Scholar 

  76. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.

    PubMed  Google Scholar 

  77. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001;97:1196–201.

    PubMed  CAS  Google Scholar 

  78. Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J, Shaughnessy P, Hymes S, Kim S, Wayne AS, Chien JW, Neumann J, Mitchell S, Syrjala K, Moravec CK, Abramovitz L, Liebermann J, Berger A, Gerber L, Schubert M, Filipovich AH, Weisdorf D, Schubert MM, Shulman H, Schultz K, Mittelman B, Pavletic S, Vogelsang GB, Martin PJ, Lee SJ, Flowers ME. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12:375–96.

    PubMed  Google Scholar 

  79. Zittoun RA, Mandelli F, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell‘Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217–23.

    PubMed  CAS  Google Scholar 

  80. Cassileth PA, Harrington DP, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649–56.

    PubMed  CAS  Google Scholar 

  81. Woods WG, Neudorf S, Gold S, et al. Children‘s Cancer Group: a comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56–62.

    PubMed  CAS  Google Scholar 

  82. Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. Leuk Res. 1999;23:709–18.

    PubMed  CAS  Google Scholar 

  83. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005;19:2304–12.

    PubMed  CAS  Google Scholar 

  84. Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission. Leuk Res. 1998;22:973–81.

    PubMed  CAS  Google Scholar 

  85. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant JP, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhéritier V, Fiere D. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075–86.

    PubMed  CAS  Google Scholar 

  86. Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, Lamy T, Pignon B, Jouet JP, Garidi R, Caillot D, Berthou C, Guyotat D, Sadoun A, Sotto JJ, Lioure B, Casassus P, Solal-Celigny P, Stalnikiewicz L, Audhuy B, Blanchet O, Baranger L, Béné MC, Ifrah N; GOELAMS (Groupe Ouest-Est des Leucémies Airguës et Maladies du Sang) Group. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004;104:3028–37.

    PubMed  CAS  Google Scholar 

  87. Fielding AK, Richards SM, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109:944–50.

    PubMed  CAS  Google Scholar 

  88. Radich JP, Gooley T, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003;102:31–5.

    PubMed  CAS  Google Scholar 

  89. Giralt SA, Arora M, et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. 2007;137:461–7.

    PubMed  CAS  Google Scholar 

  90. Crawley C, Iacobelli S, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588–94.

    PubMed  CAS  Google Scholar 

  91. Weisser M, Schleuning M, et al. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma. 2007;48:295–301.

    PubMed  CAS  Google Scholar 

  92. Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002;100:1997–2004.

    PubMed  CAS  Google Scholar 

  93. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low risk myelodysplasia is associated with improved outcome. Blood 2004;104:579–85.

    PubMed  CAS  Google Scholar 

  94. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23:9387–93.

    PubMed  CAS  Google Scholar 

  95. Martino R, Iacobelli S, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006;108:836–46.

    PubMed  CAS  Google Scholar 

  96. Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin‘s lymphoma. Blood 1994;84:1050–5.

    PubMed  CAS  Google Scholar 

  97. Bierman PJ, Sweetenham JW, Loberiza FR Jr, et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin‘s lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003;21:3744–53.

    PubMed  Google Scholar 

  98. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310–6.

    PubMed  CAS  Google Scholar 

  99. Grigg A, Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant. 2004;10:579–90.

    PubMed  CAS  Google Scholar 

  100. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin‘s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005;365:1934–41.

    PubMed  Google Scholar 

  101. Barlogie B, Kyle RA, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929–36.

    PubMed  CAS  Google Scholar 

  102. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110–20.

    PubMed  CAS  Google Scholar 

  103. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750–8.

    PubMed  CAS  Google Scholar 

  104. Bishop MR, Fowler DH, Marchigiani D, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol. 2004;22:3886–92.

    PubMed  Google Scholar 

  105. Carella AM, Beltrami G, Corsetti MT, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005;366:318–320.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. M.D. Anderson Cancer Center, Houston, TX, USA

    Sergio Giralt

Authors
  1. Sergio Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael R. Bishop
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sergio Giralt .

Editor information

Editors and Affiliations

  1. Weeping Cherry Drive 14015 , Rockville, 20850, U.S.A.

    Michael R. Bishop

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Giralt, S., Bishop, M.R. (2009). Principles and Overview of Allogeneic Hematopoietic Stem Cell Transplantation. In: Bishop, M. (eds) Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, vol 144. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-78580-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-78580-6_1

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-78579-0

  • Online ISBN: 978-0-387-78580-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation